Publication:
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Simple item page
dc.contributor.authorBAYOĞLU, İBRAHİM VEDAT
dc.contributor.authorsKaracin C., Oksuzoglu B., Demirci A., KESKİNKILIÇ M., Baytemür N. K., Yılmaz F., Selvi O., Erdem D., Avşar E., Paksoy N., et al.
dc.date.accessioned2023-02-20T08:08:17Z
dc.date.available2023-02-20T08:08:17Z
dc.date.issued2023-02-10
dc.description.abstract© 2023. The Author(s).BACKGROUND: There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to show the effectiveness of systemic treatments after CDKi and whether there is a survival difference between hormonal treatments (monotherapy vs. mTOR-based). METHODS: A total of 609 patients from 53 centers were included in the study. Progression-free-survivals (PFS) of subsequent treatments (chemotherapy (CT, n:434) or endocrine therapy (ET, n:175)) after CDKi were calculated. Patients were evaluated in three groups as those who received CDKi in first-line (group A, n:202), second-line (group B, n: 153) and ≥ 3rd-line (group C, n: 254). PFS was compared according to the use of ET and CT. In addition, ET was compared as monotherapy versus everolimus-based combination therapy. RESULTS: The median duration of CDKi in the ET arms of Group A, B, and C was 17.0, 11.0, and 8.5 months in respectively; it was 9.0, 7.0, and 5.0 months in the CT arm. Median PFS after CDKi was 9.5 (5.0-14.0) months in the ET arm of group A, and 5.3 (3.9-6.8) months in the CT arm (p = 0.073). It was 6.7 (5.8-7.7) months in the ET arm of group B, and 5.7 (4.6-6.7) months in the CT arm (p = 0.311). It was 5.3 (2.5-8.0) months in the ET arm of group C and 4.0 (3.5-4.6) months in the CT arm (p = 0.434). Patients who received ET after CDKi were compared as those who received everolimus-based combination therapy versus those who received monotherapy ET: the median PFS in group A, B, and C was 11.0 vs. 5.9 (p = 0.047), 6.7 vs. 5.0 (p = 0.164), 6.7 vs. 3.9 (p = 0.763) months. CONCLUSION: Physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown that subsequent ET after CDKi can be as effective as CT. It was also observed that better PFS could be achieved with the subsequent everolimus-based treatments after first-line CDKi compared to monotherapy ET.
dc.identifier.citationKaracin C., Oksuzoglu B., Demirci A., KESKİNKILIÇ M., Baytemür N. K., Yılmaz F., Selvi O., Erdem D., Avşar E., Paksoy N., et al., "Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy", BMC cancer, cilt.23, sa.1, ss.136, 2023
dc.identifier.doi10.1186/s12885-023-10609-8
dc.identifier.endpage136
dc.identifier.issn1471-2407
dc.identifier.issue1
dc.identifier.startpage136
dc.identifier.urihttps://avesis.marmara.edu.tr/api/publication/78fc1821-e830-4912-a671-d972cab74a97/file
dc.identifier.urihttps://hdl.handle.net/11424/286555
dc.identifier.volume23
dc.language.isoeng
dc.relation.ispartofBMC cancer
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectTıbbi Genetik
dc.subjectYaşam Bilimleri
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectSitogenetik
dc.subjectSağlık Bilimleri
dc.subjectTemel Bilimler
dc.subjectMedicine
dc.subjectInternal Medicine Sciences
dc.subjectInternal Diseases
dc.subjectOncology
dc.subjectMedical Genetics
dc.subjectLife Sciences
dc.subjectMolecular Biology and Genetics
dc.subjectCytogenetic
dc.subjectHealth Sciences
dc.subjectNatural Sciences
dc.subjectKlinik Tıp (MED)
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.subjectBİYOKİMYA VE MOLEKÜLER BİYOLOJİ
dc.subjectGENETİK VE KALITIM
dc.subjectClinical Medicine (MED)
dc.subjectLife Sciences (LIFE)
dc.subjectCLINICAL MEDICINE
dc.subjectMOLECULAR BIOLOGY & GENETICS
dc.subjectONCOLOGY
dc.subjectBIOCHEMISTRY & MOLECULAR BIOLOGY
dc.subjectGENETICS & HEREDITY
dc.subjectGenetik
dc.subjectKanser Araştırmaları
dc.subjectGenetics
dc.subjectCancer Research
dc.subjectAdvanced breast cancer
dc.subjectCyclin-dependent kinase
dc.subjectEndocrine treatment
dc.subjectEverolimus
dc.subjectFulvestrant
dc.subjectHormonotherapy
dc.subjectPalbociclib
dc.subjectRibociclib
dc.titleEfficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
dc.typearticle
dspace.entity.typePublication
local.avesis.id78fc1821-e830-4912-a671-d972cab74a97
local.indexed.atPUBMED
local.indexed.atSCOPUS
relation.isAuthorOfPublicationd4f139e7-cf36-415c-a82e-a9c7956ecede
relation.isAuthorOfPublication.latestForDiscoveryd4f139e7-cf36-415c-a82e-a9c7956ecede

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
file.pdf
Size:
1.57 MB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs